Diagnostic value of KLK6 as an ovarian cancer biomarker: A meta-analysis

Yang,Fan; Hu,Zhi‑De; Chen,Yingjian; Hu,Cheng‑Jin

doi:10.3892/br.2016.662

Diagnostic value of KLK6 as an ovarian cancer biomarker: A meta-analysis

Authors:
- Fan Yang
- Zhi‑De Hu
- Yingjian Chen
- Cheng‑Jin Hu
View Affiliations

Affiliations: Graduate School of Jinzhou Medical University, Jinzhou, Liaoning 121001, P.R. China, Department of Laboratory Medicine, General Hospital of Ji'nan Military Command Region, Ji'nan, Shandong 250031, P.R. China
Published online on: April 21, 2016 https://doi.org/10.3892/br.2016.662
Pages: 681-686
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Kallikrein-related peptidase 6 (KLK6) is a new potential serum biomarker of ovarian cancer. The aim of the present study was to assess the diagnostic value of KLK6 systematically for ovarian cancer. All the selected studies regarding the changes of KLK6 in ovarian cancer were published prior to April 2015. Five studies involving 485 patients with ovarian cancer, 420 benign cysts and 245 healthy controls met the inclusion criteria. The value of sensitivity, specificity, positive‑likelihood ratio (LR+), negative‑likelihood ratio (LR‑) and area under the receiver operating characteristic curve (ROC) were obtained. All these indices were used to evaluate the diagnostic value of KLK6 for ovarian cancer. The values of sensitivity, specificity, LR+ and LR‑ (95% confidence interval) of KLK6 were 0.50 (0.47‑0.54), 0.91 (0.89‑0.93), 7.20 (3.34‑15.52) and 0.51 (0.43‑0.62), respectively. The area under the summary ROC of KLK6 was 0.86. The index of Q* was 0.79. In conclusion, KLK6 showed high specificity for the diagnosis of ovarian cancer. It can improve the diagnostic accuracy of cancer antigen 125 (CA125). A combined panel of CA125 and KL K6 shows a high diagnostic efficiency for advanced ovarian cancer. Owing to the small number of studies and lack of samples, additional studies meeting the inclusion criteria are required to further analyze the diagnostic value of KLK6 for ovarian cancer.

View Figures

View References

1	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
2	Rosenthal AN and Jacobs IJ: The role of CA 125 in screening for ovarian cancer. Int J Biol Markers. 13:216–220. 1998.PubMed/NCBI
3	Maggino T and Gadducci A: Serum markers as prognostic factors in epithelial ovarian cancer: An overview. Eur J Gynaecol Oncol. 21:64–69. 2000.PubMed/NCBI
4	Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z and Mills GB: CA 125: The past and the future. Int J Biol Markers. 13:179–187. 1998.PubMed/NCBI
5	Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, et al: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 309:883–887. 1983. View Article : Google Scholar : PubMed/NCBI
6	Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP, Fritz H, Lilja H, Malm J, Maltais LJ, et al: A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem. 387:637–641. 2006. View Article : Google Scholar : PubMed/NCBI
7	Yousef GM and Diamandis EP: The new human tissue kallikrein gene family: Structure, function, and association to disease. Endocr Rev. 22:184–204. 2001. View Article : Google Scholar : PubMed/NCBI
8	Diamandis EP, Yousef GM, Soosaipillai AR and Bunting P: Human kallikrein 6 (zyme/protease M/neurosin): A new serum biomarker of ovarian carcinoma. Clin Biochem. 33:579–583. 2000. View Article : Google Scholar : PubMed/NCBI
9	Diamandis EP, Yousef GM, Soosaipillai AR, Grass L, Porter A, Little S and Sotiropoulou G: Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clin Biochem. 33:369–375. 2000. View Article : Google Scholar : PubMed/NCBI
10	Diamandis EP, Scorilas A, Fracchioli S, Van Gramberen M, De Bruijn H, Henrik A, Soosaipillai A, Grass L, Yousef GM, Stenman UH, et al: Human kallikrein 6 (hK6): A new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol. 21:1035–1043. 2003. View Article : Google Scholar : PubMed/NCBI
11	Luo LY, Bunting P, Scorilas A and Diamandis EP: Human kallikrein 10: a novel tumor marker for ovarian carcinoma? Clinica Chim Acta. 306:11–118. 2001. View Article : Google Scholar
12	Chen X, Li WL, Zhang YL, Wu Q, Guo YM and Bai ZL: Meta-analysis of quantitative diffusion-weighted MR imaging in the differential diagnosis of breast lesions. BMC Cancer. 10:6932010. View Article : Google Scholar : PubMed/NCBI
13	Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA and Bossuyt PM: QUADAS-2 Group: QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 155:529–536. 2011. View Article : Google Scholar : PubMed/NCBI
14	Zamora J, Abraira V, Muriel A, Khan K and Coomarasamy A: Meta-DiSc: A software for meta-analysis of test accuracy data. BMC Med Res Methodol. 6:312006. View Article : Google Scholar : PubMed/NCBI
15	Bandiera E, Zanotti L, Fabricio AS, Bucca E, Squarcina E, Romani C, Tassi R, Bignotti E, Todeschini P, Tognon G, et al: Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. Clin Chem Lab Med. 51:1815–1824. 2013. View Article : Google Scholar : PubMed/NCBI
16	Koh SC, Huak CY, Lutan D, Marpuang J, Ketut S, Budiana NG, Saleh AZ, Aziz MF, Winarto H, Pradjatmo H, et al: Combined panel of serum human tissue kallikreins and CA-125 for the detection of epithelial ovarian cancer. J Gynecol Oncol. 23:175–181. 2012. View Article : Google Scholar : PubMed/NCBI
17	El Sherbini MA, Sallam MM, Shaban EA and El-Shalakany AH: Diagnostic value of serum kallikrein-related peptidases 6 and 10 versus CA125 in ovarian cancer. IInt J Gynecol Cancer. 21:625–632. 2011. View Article : Google Scholar
18	Campos SM and Ghosh S: A current review of targeted therapeutics for ovarian cancer. J Oncol. 2010:1493622010. View Article : Google Scholar : PubMed/NCBI
19	Mills GB, Bast RC Jr and Srivastava S: Future for ovarian cancer screening: Novel markers from emerging technologies of transcriptional profiling and proteomics. J Natl Cancer Inst. 93:1437–1439. 2001. View Article : Google Scholar : PubMed/NCBI
20	Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM and Kleijnen J: Sources of variation and bias in studies of diagnostic accuracy: A systematic review. Ann Intern Med. 140:189–202. 2004. View Article : Google Scholar : PubMed/NCBI